In recent years, Pfizer has been a fateful journey. Not only did AstraZeneca fail to marry, but it also responded slowly in the red-and-violet tumor-immune market, and lost the number one global drug sales for the first time in ten years. Although excluding exchange rate effects, the New York-based giant's first quarter 2015 revenue increased 2% from the same period last year to $10.9 billion. However, when accounting for the impact of exchange rate fluctuations, Pfizer's revenue fell by 5% year-on-year, which also continued the company's continuous decline in revenue since the 2012 best-selling drug Lipitor patent expired. At the same time, there are anti-inflammatory drugs such as Celebrex (Celebrex), antibacterial Zyvox and Viagra (Viagra), which treats sexual erectile dysfunction. In addition to the effects of exchange rate fluctuations, the downturn in Pfizer's revenue is largely due to the termination of co-promotion agreements.
However, Pfizer seems to have a glimmer of hope now. If the clinical trials of the late pipeline drugs are smooth and the regulatory aspects are not serious, the company is expected to reverse the decline in income with many potential blockbuster drugs.
At present, the pharmaceutical giant has 10 Phase III clinical trial drugs and another 12 Phase II clinical trial drugs. Pfizer is naturally confident in developing and expanding its product line. Some drugs that are still in Phase III clinical trials are expected to have sales of up to $1 billion in the first year after listing. These drugs include biosimilars for the following drugs, Johnson & Johnson's gram (Infliximab, Remicade), Roche's new formulation rituximab (rituximab, MabThera/Rituxan) and Herceptin (trastuzumab) , Herceptin). Among them, Remicade contributed $6.65 billion in revenue to Johnson & Johnson in 2014. Roche’s Herceptin revenue was $6.9 billion, while MabThera/Rituxan exceeded $7.54 billion.
If approved, only the biosimilars of these three drugs will help Pfizer achieve its goal of splitting the $21 billion market. Assuming that biosimilars are sold at 30% of the original drug, $15 billion in revenue is not an illusion for Pfizer. If Pfizer is willing to continue its efforts in the biosimilars sector, the potential revenue will be even more, as the biosimilars market will reach $20 billion by 2020.
It is estimated that by 2020, the global non-patent injection business will reach 70 billion US dollars. Currently, Pfizer has 9.9% of its revenue from the vaccine business. The company also realizes that there is still a lot of profit in this field. Recently, it acquired specialty injections and infusions. The technology company Hospira, to enhance the line of generic injectable pharmaceutical and biosimilar products.
In addition, Pfizer has signed a series of cooperation agreements on the development and commercialization of anticancer drugs, in cooperation with BIND Therapeutics. According to analyst speculation, Pfizer may also acquire Clovis Oncology Inc. in Colorado, which may further advance Pfizer's two breakthrough cancer therapies in the field of cancer.
Rechargeable Hearing Aid
Rechargeable Hearing Aid
Shenzhen Sunshine Technology Co.,Ltd , https://www.shenzhenyatwin.com